DE256747T1 - Morphologisch homogene formen von famotidine und verfahren zu deren herstellung. - Google Patents

Morphologisch homogene formen von famotidine und verfahren zu deren herstellung.

Info

Publication number
DE256747T1
DE256747T1 DE198787306882T DE87306882T DE256747T1 DE 256747 T1 DE256747 T1 DE 256747T1 DE 198787306882 T DE198787306882 T DE 198787306882T DE 87306882 T DE87306882 T DE 87306882T DE 256747 T1 DE256747 T1 DE 256747T1
Authority
DE
Germany
Prior art keywords
famotidine
process according
preparation
solution
temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE198787306882T
Other languages
English (en)
Inventor
Zsuzsanna H-1201 Budapest Aracs
Peter H-2230 Gyomro Bod
Erik H-1121 Budapest Bogsch
Eva H-1102 Budapest Fekecs
Kalman H-1126 Budapest Harsanyi
Bela H-1113 Budapest Hegedus
Sandor H-1173 Budapest Miszori
Imre H-1111 Budapest Peter
Maria H-1025 Budapest Stiller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Vegyeszeti Gyar Nyrt
Original Assignee
Richter Gedeon Vegyeszeti Gyar RT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10963778&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE256747(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Richter Gedeon Vegyeszeti Gyar RT filed Critical Richter Gedeon Vegyeszeti Gyar RT
Publication of DE256747T1 publication Critical patent/DE256747T1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (7)

47 545 o/fi Europäische Patentanmeldung Nr. 87 306 882.9 Veröffentlichungs-Nr.: 0 256 747 Anmelder: RICHTER GEDEON VEGYESZETI Budapest /Ungarn PATENTANSPRÜCHE
1. Form "A" von Famotidin mit einem endothermen Schmelzmaximum bei 1670C bestimmt durch DSC und charakteristischen Absorptionsbanden im Infrarotspektrum bei 3450, 1670, 1138 und 611 < Schmelzpunkt von 167 - 1700C.
bei 3450, 1670, 1138 und 611 cm"1 und mit einem
2. Form "B" von Famotidin mit einem endothermen Schmelzmaximum von 1590C, bestimmt duch DSC und einer charakterischen Absorptionsbande im Infrarotspektrum bei 3506, 3103 ui
von 159 - 1620C.
bei 3506, 3103 und 777 cm und mit einem Schmelzpunkt
3. Verfahren zur Herstellung von morphologisch homogenem Farmotidin £ N-sulfamoyl-3-(2-guanidinothiazol-4-yl-methylthio)-propionamidin J, dadurch gekennzeichnet , daß man
Famotidin mit einer beliebigen morphologischen Zusammensetzung in Wasser und/oder einem niedrigen aliphatischen Alkohol unter Erwärmen auflöst und
a) im Falle der Herstellung der Form "A" die heiße gesättigte Lösung unter Anwendung einer Kühlgeschwindigkeit von eta 1°C/min oder weniger, kristallisiert, oder
b) im Falle der Herstellung der Form "B" das Produkt aus dessen übersättigten Lösung, die bei einer Temperatur unterhalb 4O0C übersättigt worden ist, ausfällt,
und das gewünschte Produkt von der erhaltenen Kristallsuspension abtrennt.
4. Verfahren gemäß Anspruch 3, bei dem man Keimkristalle der gewünschten Form zu dem Kristallisationssystem zugibt.
5. Verfahren gemäß Anspruch 3, bei dem man die Trennung bei einer Temperatur zwischen -100C und +400C durchführt.
6. Verfahren gemäß Anspruch 5, bei dem man die Trennung bei einer Temperatur zwischen +1O0C und +200C durchführt.
7. Verfahren gemäß Anspruch 3, Variante b), bei dem man die übersättigte Lösung aus einer heißen Lösung durch Abkühlen mit einer Kühlgeschwindigkeit von mehr als 10°C/min oder durch Freisetzen der freien Base von Famotidin aus dessen Salz herstellt.
DE198787306882T 1986-08-05 1987-08-04 Morphologisch homogene formen von famotidine und verfahren zu deren herstellung. Pending DE256747T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU863370A HU196775B (en) 1986-08-05 1986-08-05 Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances

Publications (1)

Publication Number Publication Date
DE256747T1 true DE256747T1 (de) 1988-11-24

Family

ID=10963778

Family Applications (2)

Application Number Title Priority Date Filing Date
DE198787306882T Pending DE256747T1 (de) 1986-08-05 1987-08-04 Morphologisch homogene formen von famotidine und verfahren zu deren herstellung.
DE3782576T Expired - Lifetime DE3782576T3 (de) 1986-08-05 1987-08-04 Morphologisch homogene Formen von Famotidin und Verfahren zu deren Herstellung.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE3782576T Expired - Lifetime DE3782576T3 (de) 1986-08-05 1987-08-04 Morphologisch homogene Formen von Famotidin und Verfahren zu deren Herstellung.

Country Status (18)

Country Link
US (3) US4894459A (de)
EP (1) EP0256747B2 (de)
JP (2) JP2644234B2 (de)
KR (1) KR940003954B1 (de)
CN (1) CN1024275C (de)
AR (1) AR243175A1 (de)
AT (1) ATE82274T1 (de)
AU (1) AU604040B2 (de)
BG (1) BG60496B2 (de)
CA (1) CA1265809A (de)
CS (1) CS268188B2 (de)
DE (2) DE256747T1 (de)
DK (1) DK175022B1 (de)
FI (1) FI89917C (de)
GR (1) GR871216B (de)
HU (1) HU196775B (de)
PH (1) PH24069A (de)
PT (1) PT85473B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO882037L (no) * 1987-06-22 1988-12-23 Marga Para La Investigacion Sa Famotidin, polymerte former og fremstilling derav.
ATE208615T1 (de) * 1993-07-09 2001-11-15 Scherer Corp R P Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen
US6939873B2 (en) * 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
US7683071B2 (en) * 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US6756379B2 (en) * 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
TWI353979B (en) * 2002-04-10 2011-12-11 Nippon Zoki Pharmaceutical Co Novel crystal form of 5-hydroxy-1-methylhydantoin
CA2426122A1 (en) * 2002-05-02 2003-11-02 M/S Tonira Pharma Limited A process for the preparation of a combination of famotidine polymorphis a and b
TW200409746A (en) * 2002-07-26 2004-06-16 Theravance Inc Crystalline β2 adrenergic receptor agonist
AR042444A1 (es) 2002-12-11 2005-06-22 Taro Pharmaceuticals Ireland L Metodo para el tratamiento de desordenes del movimiento mediante la utilizacion de acido barbiturico
TW200510277A (en) * 2003-05-27 2005-03-16 Theravance Inc Crystalline form of β2-adrenergic receptor agonist
EP1781624A4 (de) * 2004-07-02 2010-06-23 Taro Pharma Ind Verfahren zur herstellung von 1-methoxymethyl-5,5-diphenylbarbitursäure
EP1919288A4 (de) * 2005-07-18 2009-12-16 Horizon Therapeutics Inc Famotidin- und ibuprofenhaltige arzneimittel und ihre verabreichung
US20080021078A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
US8067451B2 (en) * 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US20080020040A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
WO2008011426A2 (en) 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
WO2008027963A2 (en) * 2006-08-31 2008-03-06 Horizon Therapeutics, Inc. Nsaid dose unit formulations with h2-receptor antagonists and methods of use
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
EP2081576A4 (de) * 2006-11-14 2010-06-30 Taro Pharmaceuticals North Ame Verfahren zur verbesserung der bioverfügbarkeit für nichtsedierende barbiturate
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
TW201011043A (en) * 2008-06-20 2010-03-16 Chugai Pharmaceutical Co Ltd Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives
WO2015163832A1 (en) 2014-04-25 2015-10-29 Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. An ibuprofen and famotidine combined composition having improved stability
TR201618765A2 (tr) 2016-12-16 2018-07-23 Imuneks Farma Ilac Sanayi Ve Ticaret Anonim Sirketi Ağrı ve enflamasyonun tedavisi için steroid olmayan anti-enflamatuvar ilaçlar ve H2 reseptörü antagonisti kombinasyonları.
US11331307B2 (en) 2020-07-15 2022-05-17 Schabar Research Associates, Llc Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1543238A (en) * 1976-09-21 1979-03-28 Smith Kline French Lab Polymorph of cimetidine
JPS6056143B2 (ja) * 1979-08-02 1985-12-09 山之内製薬株式会社 アミジン誘導体ならびにその製造法
JPS5655383A (en) * 1979-10-12 1981-05-15 Yamanouchi Pharmaceut Co Ltd Amizine derivative and its preparation
HU185457B (en) * 1981-09-25 1985-02-28 Richter Gedeon Vegyeszet Process for preparating cimetidine-z
US4496737A (en) * 1982-09-27 1985-01-29 Merck & Co., Inc. Process for preparing sulfamylamidine antisecretory agents
JPS59227870A (ja) * 1983-06-07 1984-12-21 Yamanouchi Pharmaceut Co Ltd 新規２−グアニジノチアゾリン誘導体ならびにその製造法
HU194845B (en) * 1985-09-11 1988-03-28 Richter Gedeon Vegyeszet Process for production of n-sulphamil-3-/2-guanidintiazolil-4-methil-tio/-propion-amidin
DE3644246A1 (de) * 1986-06-20 1987-12-23 Uriach & Cia Sa J Verfahren zur herstelung von 3-(((2-((aminoiminomethyl)-amino)-4-thiazolyl)-methyl)-thio)-n-(aminosulfonyl)-propanimidamid
GB8618847D0 (en) * 1986-08-01 1986-09-10 Smith Kline French Lab Pharmaceutical formulations
NO882037L (no) * 1987-06-22 1988-12-23 Marga Para La Investigacion Sa Famotidin, polymerte former og fremstilling derav.

Also Published As

Publication number Publication date
JPS6399065A (ja) 1988-04-30
FI873346A0 (fi) 1987-08-03
ATE82274T1 (de) 1992-11-15
CS268188B2 (en) 1990-03-14
EP0256747B2 (de) 2001-11-28
GR871216B (en) 1987-11-19
DK404187A (da) 1988-02-06
FI89917B (fi) 1993-08-31
US5120850A (en) 1992-06-09
DK175022B1 (da) 2004-04-26
DE3782576D1 (de) 1992-12-17
US4894459A (en) 1990-01-16
CN1024275C (zh) 1994-04-20
AR243175A1 (es) 1993-07-30
HUT45240A (en) 1988-06-28
PT85473A (en) 1987-09-01
EP0256747B1 (de) 1992-11-11
HU196775B (en) 1989-01-30
BG60496B2 (bg) 1995-05-31
JP2644234B2 (ja) 1997-08-25
CN87105373A (zh) 1988-06-08
KR880002847A (ko) 1988-05-11
KR940003954B1 (ko) 1994-05-09
JP2708715B2 (ja) 1998-02-04
FI89917C (fi) 1993-12-10
PT85473B (pt) 1990-06-29
AU604040B2 (en) 1990-12-06
DK404187D0 (da) 1987-08-03
DE3782576T2 (de) 1993-03-25
EP0256747A1 (de) 1988-02-24
DE3782576T3 (de) 2002-08-08
AU7654287A (en) 1988-02-11
US5128477A (en) 1992-07-07
JPH07316141A (ja) 1995-12-05
PH24069A (en) 1990-03-05
FI873346A (fi) 1988-02-06
CA1265809A (en) 1990-02-13
CS579987A2 (en) 1989-04-14

Similar Documents

Publication Publication Date Title
DE256747T1 (de) Morphologisch homogene formen von famotidine und verfahren zu deren herstellung.
DE3529529A1 (de) Verfahren zur herstellung einer stabilen modifikation von torasemid
DE2060683C2 (de) Verfahren zur Isolierung von reinem kubischen oder hartem hexagonalen Bornitrid
DE1021831B (de) Verfahren zur Herstellung von reinem kristallisiertem Ammoniumbifluorid aus Fluokieselsaeure und Ammoniak
DE1667604B1 (de) Verfahren zur herstellung von kristallinem cadmiumtellurid
Leckebusch Zur gelzüchtung von Flourperovskiten AMnF3 (A= K, Rb, NH4, Tl, Cs)
JPS5365997A (en) Manufacturing process of tantalum acid lithium single crystal
EP1213262A1 (de) Verfahren zur Herstellung von höchstkonzentriertem Wasserstoffperoxid und hiermit erhältliches mindestens 99,9 gew.-%iges Wasserstoffperoxid
DE2133875A1 (de) Verfahren zum ziehen von einkristallen, insbesondere fuer keimkristalle
DE726507C (de) Verfahren und Vorrichtung zur Herstellung von grobkoernigem Ammoniumbicarbonat
DE960096C (de) Verfahren zur Herstellung von ª†-Hexachlorcyclohexan mit einem ª† -Isomerengehalt von mindestens 90%
DE697141C (de) Verfahren zur Herstellung von lagerbestaendigem, gut streubarem Harnstoff
DE2316393B1 (de) Verfahren zum herstellen von verlorenen giessereimodellen
DE3831305C2 (de)
DE19626868C2 (de) Verfahren zur Herstellung von Goldkristallen
DE715906C (de) Verfahren zur Herstellung von Kaliumsulfat aus Syngenit
DE3918327C2 (de)
EP0218842A3 (de) Verfahren zur Herstellung von beta-Zinkdiphosphid-Einkristallen
DE645725C (de) Herstellung von Alkalinitraten aus Alkalichloriden und Salpetersaeure
DE1592455C (de) Verfahren zum Zuchten von Vanadium dioxyd Einkristallen
DE1015422B (de) Verfahren zum Reinigen von Terephthalsaeure
DE1667604C (de) Verfahren zur Herstellung von kristallinem Cadmiumtellurid
DE2426282A1 (de) Kristallines naoh.3,5 h tief 2 o und verfahren zu seiner herstellung
AT208337B (de) Verfahren zur Herstellung von Natrium-1,5-borat
JPS5792599A (en) Production of single crystal of ferrite